ALT vs. VERA, IRON, SDGR, GLPG, MESO, IDYA, KNSA, AAPG, WVE, and IMCR
Should you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Vera Therapeutics (VERA), Disc Medicine (IRON), Schrödinger (SDGR), Galapagos (GLPG), Mesoblast (MESO), IDEAYA Biosciences (IDYA), Kiniksa Pharmaceuticals (KNSA), Ascentage Pharma Group International (AAPG), Wave Life Sciences (WVE), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry.
Altimmune vs.
Vera Therapeutics (NASDAQ:VERA) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.
In the previous week, Altimmune had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 6 mentions for Altimmune and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.74 beat Altimmune's score of 0.80 indicating that Vera Therapeutics is being referred to more favorably in the media.
Altimmune has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.
Vera Therapeutics presently has a consensus target price of $64.67, suggesting a potential upside of 139.95%. Altimmune has a consensus target price of $20.83, suggesting a potential upside of 253.71%. Given Altimmune's higher possible upside, analysts clearly believe Altimmune is more favorable than Vera Therapeutics.
Altimmune received 20 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 72.62% of users gave Altimmune an outperform vote while only 66.13% of users gave Vera Therapeutics an outperform vote.
99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 21.7% of Vera Therapeutics shares are owned by insiders. Comparatively, 4.1% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Vera Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -199,076.92%. Vera Therapeutics' return on equity of -50.13% beat Altimmune's return on equity.
Vera Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
Summary
Vera Therapeutics beats Altimmune on 9 of the 17 factors compared between the two stocks.
Get Altimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Altimmune Competitors List
Related Companies and Tools
This page (NASDAQ:ALT) was last updated on 3/26/2025 by MarketBeat.com Staff
Buy ALT Stock Free ALT Stock Alerts